Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Study ID
- NCT01522183
- Status
- Recruiting
Conditions
- Atypical Hemolytic-Uremic Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Key Dates
- Start date
- Mar 18, 2013
- Status verified
- Sep 2025
- Primary completion
- Jan 1, 2031
- Completion
- Jan 1, 2031
Study Design
- Enrollment
- 3,000 participants (estimated)
Primary Outcome Measure
Proportion of patients who experience specified events [ Time Frame: 10 years ]
Central Contacts
- Alexion Pharmaceuticals, Inc. (Sponsor)1-855-752-2356
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Clinical Trial Site | Aurora | Colorado | 80045 | Dixon |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20007 | Broome |
| Clinical Trial Site | Gainesville | Florida | 32610 | Segal |
| Clinical Trial Site | Atlanta | Georgia | 30322 | Greenbaum |
| Clinical Trial Site | Chicago | Illinois | 60614 | - |
| Clinical Trial Site | Boston | Massachusetts | 02115 | Alenizi |
| Clinical Trial Site | St Louis | Missouri | 63110 | Majerus |
| Clinical Trial Site | Winston-Salem | North Carolina | 27103 | - |
| Clinical Trial Site | Columbus | Ohio | 43210 | - |